219 related articles for article (PubMed ID: 3160180)
1. [Therapy of virginal prostatic cancer with cyproterone acetate].
Maier U
Z Urol Nephrol; 1985 Apr; 78(4):181-7. PubMed ID: 3160180
[TBL] [Abstract][Full Text] [Related]
2. [Therapy of prostatic cancer with cyproterone acetate].
Maier U
Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
[TBL] [Abstract][Full Text] [Related]
3. [Cyproterone acetate and cancer of the prostate. Experience in 46 cases].
Tauveron I; Hermabessière J
Therapie; 1988 May; 43(3):175-7. PubMed ID: 2971277
[No Abstract] [Full Text] [Related]
4. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
[TBL] [Abstract][Full Text] [Related]
5. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
Debruyne FM
Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
[TBL] [Abstract][Full Text] [Related]
6. [Cancers of the prostate and cyproterone acetate. Value of blood testosterone and PSA levels for treatment surveillance].
Aubert J; Dore B; Irani J; Bon D
J Urol (Paris); 1990; 96(8):431-5. PubMed ID: 1707083
[TBL] [Abstract][Full Text] [Related]
7. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
Borgmann V; al-Abadi H; Nagel R
Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
[TBL] [Abstract][Full Text] [Related]
8. Treatment of prostatic cancer with cyproterone acetate as monotherapy.
Beurton D; Grall J; Davody P; Cukier J
Prog Clin Biol Res; 1987; 243A():369-77. PubMed ID: 2958861
[No Abstract] [Full Text] [Related]
9. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
10. Cyproterone acetate as monotherapy in prospective randomized trials.
de Voogt HJ
Prog Clin Biol Res; 1990; 359():85-91; discussion 105-7. PubMed ID: 2149459
[No Abstract] [Full Text] [Related]
11. [Evaluation of efficacy of cyproterone acetate monotherapy in prostatic cancer].
Gurina LI; Iudin SV; Rusakov IG; Bystrov AA
Urologiia; 2003; (4):25-30. PubMed ID: 12942722
[TBL] [Abstract][Full Text] [Related]
12. Initiation of LHRH monotherapy for prostate cancer.
Milsted RA
Prog Clin Biol Res; 1989; 303():69-74. PubMed ID: 2528742
[No Abstract] [Full Text] [Related]
13. [Chemotherapy of advanced prostate cancer].
Hofmann W; Langkopf B
Z Urol Nephrol; 1986 Jan; 79(1):33-9. PubMed ID: 2938361
[No Abstract] [Full Text] [Related]
14. [Transrectal echography and cancer of the prostate. III. Monitoring of the treatment response].
Abad Menor F; Espuela Orgaz R; Pérez Arbej JA; Nogueras Gimeno MA; Martínez Pérez E; Arnaiz Esteban F
Arch Esp Urol; 1990 Apr; 43(3):265-7. PubMed ID: 2142406
[TBL] [Abstract][Full Text] [Related]
15. Initial treatment of prostatic cancer by endocrine measures and cytotoxic drugs.
Tunn UW; Goldschmidt AJ; Peter K; Becker M
Prog Clin Biol Res; 1990; 359():165-76; discussion 177-80. PubMed ID: 2149458
[No Abstract] [Full Text] [Related]
16. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
17. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
Varenhorst E; Wallentin L; Carlström K
Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
[TBL] [Abstract][Full Text] [Related]
18. Use of cyproterone acetate in prostate cancer.
Goldenberg SL; Bruchovsky N
Urol Clin North Am; 1991 Feb; 18(1):111-22. PubMed ID: 1825143
[TBL] [Abstract][Full Text] [Related]
19. [Cyproterone acetate (Androcur-depo) in the treatment of inoperable prostatic cancer].
Stepanov VN; Goriunov VG; Chechenin MG; Sivkov AV; Gubdurakhmanov II
Urol Nefrol (Mosk); 1995; (6):33-6. PubMed ID: 8686122
[TBL] [Abstract][Full Text] [Related]
20. [Modification of the echographic pattern of carcinoma of the prostate treated with Lh-rh agonists].
Broseta E; Boronat F; Domínguez C; Vidal J; Llopis B; Jiménez-Cruz JF
Arch Esp Urol; 1989 Mar; 42(2):125-8. PubMed ID: 2660756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
